secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inspire Medical Systems, Inc. (INSP)
CIK:        0001609550
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001609550-25-000003
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inspire Medical reports Q4 revenue ~$239.7M (+25% YoY); issues 2025 guidance $940-955M
--------------------------------------------------------------------------------

- Preliminary Q4 2024 revenue ~$239.5-239.7M, up 25% YoY; full year 2024 revenue ~$802.6-802.8M, up 28% YoY.
- Initial FY2025 revenue guidance of $940-955M, representing 17-19% growth over FY2024.
- Soft launch of Inspire V neurostimulator with over 40 implants completed in Singapore and U.S.
- Appointed Jason Kelly as Chief Manufacturing and Quality Officer effective Jan 20, 2025; Dr. Sparks, CMO, left.
- Activated 72 new U.S. centers in Q4 (total 1,435); 12 new sales territories (total 335).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1609550/000160955025000003/0001609550-25-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1609550/000160955025000003/insp-20250113.htm
  HTML page:      https://secwatch.observer/filing/0001609550-25-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer